Biotech News

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

Ascendis Pharma (ASND)Ascendis PharmaCompany update

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon ® PTH (palopegteriparatide) for up to

Related news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

Stock data

Close
255.96 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States